teprotumumab
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
| Synonym: | anti-IGF-1 receptor human monoclonal antibody R1507 immunoglobulin G1, anti-(human insulin-like growth factor I receptor)(human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer |
|---|---|
| Code name: | R1507 RG1507 RO4858696-000 RV001 |